Determining disease severity
Yıl: 2022 Cilt: 56 Sayı: 1 Sayfa Aralığı: 3 - 5 Metin Dili: İngilizce DOI: 10.4274/turkderm.galenos.2022.76500 İndeks Tarihi: 18-07-2022
Determining disease severity
Öz: Assessment of the severity of psoriasis is versatile, and unfortunately, there is no single tool that can assess the severity of this disease in every
aspect. As well as psoriasis area and severity index, other tools such as physician’s global assessment and body surface area are also used
in assessing the severity of psoriasis. The index used to assess quality of life is the dermatology life quality index. This section discusses the
methods used in determining the severity of psoriasis, descriptions of treatment phases and goals, and measurement of treatment success.
Anahtar Kelime: Hastalık şiddetinin tanımlanması
Öz: Psoriasis şiddetinin değerlendirilmesi çok yönlüdür ve maalesef hastalığın şiddetini her yönüyle belirleyebilen bir araç yoktur. Psoriasis şiddetinin
belirlenmesinde psoriasis alan şiddet indeksi yanında, doktorun global değerlendirmesi ve vücut yüzey alanı da kullanılmaktadır. Yaşam kalitesini
değerlendirmede kullanılan indeks ise dermatoloji yaşam kalite indeksidir. Bu bölümde psoriasis şiddetinin belirlenme yöntemleri yanında, tedavi
fazlarının ve hedeflerinin tanımlanması ve tedavi başarısının belirlenmesi de değerlendirilmektedir
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Paul C, Gourraud PA, Bronsard V, et al.: Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venerol 2010;24(Suppl 2):2-9.
- 2. Langley RG, Ellis CN: Evaluating psoriasis with psoriasis area and severity ındex, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. J Am Acad Dermatol 2004;51:563-9.
- 3. Nast A, Schmitt J: Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol 2013;68:1040-1.
- 4. Radtke MA, Reich K, Spehr C, Augustin M: Treatment goals in psoriasis routine care. Arch Dermatol Res 2015;307:445-9.
- 5. Strober B, Ryan C, van de Kerkhof P, et al.: Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol 2020;82:177-22.
- 6. Mrowietz U, Kragballe K, Reich K, et al.: Definition of treatment goals for moderate to severe psoriasis:a European consensus. Arch Dermatol Res 2011;303:1-10.
- 7. Warren RB, Kleyn CE, Gulliver WP: Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. Br J Dermatol 2011;164(Suppl1):1-14.
- 8. Reich K, Mrowietz U: Treatment goals in psoriasis. J Dtsch Dermatol Ges 2007;5:566-74.
- 9. Daudén E, Puig L, Ferrándiz C, Sánchez-Carazo JL, Hernanz-Hermosa JM; Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology. J Eur Acad Dermatol Venereol 2016;30(Suppl2):1-18.
- 10. Grine L, de la Brassinne M, Ghislain PD, et al.: A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis management. J Eur Acad Dermatol Venereol 2020;34:676-84.
- 11. Armstrong AW, Siegel MP, Bagel J, et al.: From the medical board of the national psoriasis foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol 2017;76:290-8
| APA | BÜLBÜL BASKAN E (2022). Determining disease severity. , 3 - 5. 10.4274/turkderm.galenos.2022.76500 |
| Chicago | BÜLBÜL BASKAN EMEL Determining disease severity. (2022): 3 - 5. 10.4274/turkderm.galenos.2022.76500 |
| MLA | BÜLBÜL BASKAN EMEL Determining disease severity. , 2022, ss.3 - 5. 10.4274/turkderm.galenos.2022.76500 |
| AMA | BÜLBÜL BASKAN E Determining disease severity. . 2022; 3 - 5. 10.4274/turkderm.galenos.2022.76500 |
| Vancouver | BÜLBÜL BASKAN E Determining disease severity. . 2022; 3 - 5. 10.4274/turkderm.galenos.2022.76500 |
| IEEE | BÜLBÜL BASKAN E "Determining disease severity." , ss.3 - 5, 2022. 10.4274/turkderm.galenos.2022.76500 |
| ISNAD | BÜLBÜL BASKAN, EMEL. "Determining disease severity". (2022), 3-5. https://doi.org/10.4274/turkderm.galenos.2022.76500 |
| APA | BÜLBÜL BASKAN E (2022). Determining disease severity. Türkderm Türk deri hastalıkları ve frengi arşivi, 56(1), 3 - 5. 10.4274/turkderm.galenos.2022.76500 |
| Chicago | BÜLBÜL BASKAN EMEL Determining disease severity. Türkderm Türk deri hastalıkları ve frengi arşivi 56, no.1 (2022): 3 - 5. 10.4274/turkderm.galenos.2022.76500 |
| MLA | BÜLBÜL BASKAN EMEL Determining disease severity. Türkderm Türk deri hastalıkları ve frengi arşivi, vol.56, no.1, 2022, ss.3 - 5. 10.4274/turkderm.galenos.2022.76500 |
| AMA | BÜLBÜL BASKAN E Determining disease severity. Türkderm Türk deri hastalıkları ve frengi arşivi. 2022; 56(1): 3 - 5. 10.4274/turkderm.galenos.2022.76500 |
| Vancouver | BÜLBÜL BASKAN E Determining disease severity. Türkderm Türk deri hastalıkları ve frengi arşivi. 2022; 56(1): 3 - 5. 10.4274/turkderm.galenos.2022.76500 |
| IEEE | BÜLBÜL BASKAN E "Determining disease severity." Türkderm Türk deri hastalıkları ve frengi arşivi, 56, ss.3 - 5, 2022. 10.4274/turkderm.galenos.2022.76500 |
| ISNAD | BÜLBÜL BASKAN, EMEL. "Determining disease severity". Türkderm Türk deri hastalıkları ve frengi arşivi 56/1 (2022), 3-5. https://doi.org/10.4274/turkderm.galenos.2022.76500 |
